Standard Cancer Tests Miss 75% of Deadly NUT Carcinomas, Study Reveals

NUT carcinoma represents one of the most aggressive forms of cancer, with patients surviving a median of just 6.7 months after diagnosis. This rare but deadly cancer is defined by specific gene fusions involving the NUTM1 gene, most commonly with BRD4, BRD3, or NSD3 proteins. Despite its devastating prognosis, a major new study reveals that standard genetic testing methods are failing to detect the majority of cases.

Researchers analyzed 116 NUT carcinoma patients from an international registry, examining how well different diagnostic approaches could identify the cancer-defining NUTM1 fusions. The results were striking: standard DNA-based next-generation sequencing, the current gold standard for cancer genetic testing, detected only 21.6% of NUT carcinomas. Even circulating tumor DNA testing performed similarly poorly at 21.4%. In contrast, RNA-based fusion testing identified 83.9% of cases, while immunohistochemistry and FISH testing achieved near-perfect detection rates.

The patient population showed distinctive characteristics that could help clinicians recognize potential cases. The median age was just 38 years, with 40.5% being female. Remarkably, 92.9% of patients had minimal or no smoking history, distinguishing NUT carcinoma from typical lung cancers. Most tumors arose in the chest (62.9%) or head and neck regions, and the majority harbored BRD4::NUTM1 fusions (58.8%).

Beyond diagnostic challenges, the study revealed important insights into NUT carcinoma's molecular landscape. These tumors showed extremely low mutation burdens (median 1.0 mutations per megabase) and minimal PD-L1 expression (only 19.7% had ≥1% expression), suggesting limited benefit from standard immunotherapy approaches. However, researchers identified frequent co-occurring mutations in genes controlling epigenetic regulation (57% of cases), cell cycle control (26%), and DNA repair (24%), pointing toward potential therapeutic vulnerabilities.

The findings demand immediate changes to diagnostic protocols for suspected NUT carcinoma cases, emphasizing RNA-based testing or immunohistochemistry over standard DNA sequencing. The molecular insights also provide new directions for developing targeted therapies for this devastating disease.